For the full year 2025, DocGo reported total revenue of $322.2 million, down from $616.6 million in 2024. The net loss for Q4 2025 was $142.3 million, compared to a net loss of $7.6 million in Q4 2024. The annual net loss for 2025 was $196.4 million, a stark contrast to a net income of $13.4 million in 2024. The losses included several non-cash items totaling $78 million, which comprised impairments of intangible assets and goodwill.
Despite the challenges, DocGo's management remains optimistic about future growth. The company has raised its revenue guidance for 2026 to a range of $290-$310 million, up from the previous guidance of $280-$300 million. Adjusted EBITDA for 2026 is expected to be a loss of $5-$10 million, significantly improved from earlier projections of a loss of $15-$25 million. The company is also exploring strategic alternatives to maximize shareholder value, indicating a proactive approach to navigating its current challenges.
DocGo's leadership emphasized the importance of its core business lines and the growth potential in its 'healthcare at any address' services, which have shown robust demand. The company plans to hold a conference call and webcast to discuss these results and future strategies, reflecting its commitment to transparency and engagement with investors.
